Clinical trial
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
NCT00005843 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005843 |
|---|---|
| Title | R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer |
| Official title | Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | tipifarnib |
| Enrollment | 40 |
| Start date | May 1, 2000 |
| Primary completion | Sep 1, 2004 |
| First posted | Mar 5, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: